Imagion Biosystems has today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 31 March 2020. Read the
Imagion Biosystems has announced receipt of its 2019 R&D tax incentive claim of A$2,197,028 from the Australian Tax Office (ATO). In May 2019 the Company
Watch Imagion CEO Bob Proulx discuss the opportunity for MagSense® Imaging on Switzer’s CEO Masterclass: Today’s imaging technologies are limited in their ability to differentiate
Imagion Biosystems Limited wishes to advise that its Australian registered office address has changed with immediate effect to: c/o K&L Gates, Level 25, 525 Collins Street,
President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA
Appendix 4E and 2019 Full Year Results Key Developments Achieved for MagSense® Imaging Technology Imagion Biosystems has released its Appendix 4E and Preliminary Results for
Come along to Switzer Small & Micro Cap Investor Day Switzer Financial Group is pleased to bring you the Switzer Small & Micro Cap Investor
Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update
Imagion Biosystems announces the appointment of Oliver Steinbach, PhD, as Vice President of Clinical and Regulatory Affairs. Dr. Steinbach will serve as the lead executive
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance